Number and severity of adverse events among MDR-TB patients in Nigeria, 2012–2013 (N = 482).

<p>Number and severity of adverse events among MDR-TB patients in Nigeria, 2012–2013 (N = 482).</p

Association between AEs, sex, age and body weight among MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013.

<p>* <i>Adjusted Odds Ratio and p-value (Wald’s test) based on multivariate logistic regression using a stepwise backward elimination approach</i>.</p><p><i>Note</i>: <i>Treatment centers</i>: <i>DL HMH = Dr</i>. <i>Lawrence Henshaw Memorial Hospital</i>, <i>Calabar; GCH = General Chest Hospital</i>, <i>Ibadan; IDH = Infectious Disease Hospital</i>, <i>Kano; JUTH = Jos University Teaching Hospital</i>, <i>Jos; MHY = Mainland Hospital</i>, <i>Yaba; NTBLCT = National Tuberculosis and Leprosy Training Center; UCH = University College Hospital</i>, <i>Ibadan; UPTH = University of Port Harcourt Teaching Hospital; UUTH = University of Uyo Teaching Hospital</i>, <i>Uyo</i>.</p><p>Association between AEs, sex, age and body weight among MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013.</p

Baseline characteristics of MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013 (N = 482).

<p>Baseline characteristics of MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013 (N = 482).</p

Categorizing of adverse events based on signs and symptoms.

<p>Categorizing of adverse events based on signs and symptoms.</p

Grouping of adverse events of second—line anti-tuberculosis drugs.

<p>Grouping of adverse events of second—line anti-tuberculosis drugs.</p

Duration of ADRs among MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013.

<p>Duration of ADRs among MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013.</p

Pharmacovigilance Form (Yellow Form).

<p>Pharmacovigilance Form (Yellow Form).</p